Ajinomoto Bio-Pharma Services (Aji Bio-Pharma), a provider of biopharmaceutical contract development and manufacturing services, has formed an External Advisory Board (EAB) to provide insight into industry trends and high-level advice to the company’s leadership team.

Dr. Magda Marquet is co-founder and co-CEO of ALMA Life Sciences, LLC, an early stage investment firm creating and growing innovative healthcare companies. Dr. Marquet also co-founded Althea Technologies, where she led the company to become a highly profitable contract manufacturing organization, ultimately resulting in a successful sale of Althea to Ajinomoto. She also co-founded AltheaDx, a commercial stage precision medicine company with the world’s leading pharmacogenomics test for anxiety and depression.

Jim Miller is an advisor on manufacturing strategy and an authority on the biopharmaceutical contract manufacturing and development industry. He is the founder and former President of PharmSource, the industry’s principal source of market intelligence. He has advised most major CMOs on business strategy, major capital investment decisions and acquisitions; and has served on due diligence teams for high profile acquisitions made by private equity firms.

Bob Kanuga is an experienced pharmaceutical leader with a history in vaccine and biotechnology manufacturing, global procurement, contract manufacturing, licensing, mergers & acquisitions, and strategy development. He recently held the position of Vice President, Global Supply Business Development, while working at Merck for 30 years.  Bob is well-known within industry as a strong commercial and manufacturing professional.

Joseph Colleluori is a veteran pharmaceutical and chemical industry executive. In 2003, Joe joined Lonza Inc. where he successfully combined the activity and business of the small molecule and biopharmaceuticals commercial organization, which is now the foundation of Lonza Pharma & Biotech. He went on to serve as Senior Vice President responsible for Corporate Strategy, Mergers & Acquisition and Risk Management and was a member of the Capital Investment Committee. He recently held the role of Head of Biopharma Sales and Business Development for the EMEA region.